Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRC
January 20th 2024
Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.